FDA Warns of Rare Vision Loss Risk With Diabetes and Weight-Loss Drugs
Translated & summarized from Arutz Sheva by baba
The U.S. FDA has added a warning about a rare risk of sudden vision loss to labels for popular diabetes and weight-loss drugs like Ozempic and Wegovy. The condition, NAION, occurred slightly more often in patients taking these GLP-1 drugs. While the risk is low, the FDA advises patients to watch for vision changes and consult doctors, but not to stop medication without medical guidance. Israeli diabetes educators stressed the dangers of unsupervised treatment cessation.
The story in 4 lines · by baba
- FDA warns diabetes/weight-loss drugs like Ozempic may cause rare, sudden vision loss.
- The risk of NAION is low but noted in FDA review of 126 clinical trials.
- Patients should monitor for vision changes and consult doctors, not stop medication.
- Israeli diabetes educators also caution against unsupervised treatment discontinuation.
The U.S. Food and Drug Administration (FDA) has mandated an updated safety warning for certain diabetes and weight-loss medications, including popular drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. The warning addresses a rare but serious eye condition, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), which can lead to sudden and potentially irreversible vision loss.
The FDA's decision follows a comprehensive review initiated after a study published in July 2024. The review analyzed data from 126 clinical trials and found a slightly elevated incidence of NAION among patients taking GLP-1 receptor agonist drugs compared to those on placebo. Specifically, the rate was 6.4 cases per 100,000 patient-years of treatment for drug recipients, versus 3.8 cases per 100,000 patient-years for the placebo group, indicating a small but present risk.
NAION occurs due to impaired blood supply to the optic nerve, often presenting suddenly with painless vision reduction, blurred vision, or tunnel vision, typically in one eye. While the risk is low, the FDA is advising patients to be vigilant for sudden changes in vision, such as blurring, blind spots, or altered color perception. The agency recommends consulting an eye doctor and potentially temporarily halting treatment if such symptoms arise.
However, the FDA is not advising patients to stop taking these medications outright. In Israel, the Association of Diabetes Educators echoed this caution, emphasizing that abruptly discontinuing medication without medical supervision poses immediate health risks. They urged patients to consult their healthcare providers or a diabetes specialist if they have concerns about the new warning and to seek immediate ophthalmological evaluation for any sudden vision changes.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 1
